Idiopathic Pulmonary Fibrosis News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada - Dove Medical Press



Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada 
Dove Medical Press
1Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada; 2Programs for Assessment of Technology in Health (PATH), The Research Institute of St. Joe's Hamilton, St. Joseph's ...

 


Study tracks therapy to slow idiopathic pulmonary fibrosis - Medical Xpress



Medical Xpress
 
Study tracks therapy to slow idiopathic pulmonary fibrosis 
Medical Xpress
Jonathan Kropski, MD, left, talks with patient David Wainwright, who is participating in a study of a new therapy for idiopathic pulmonary fibrosis. Credit: Anne Rayner. Investigators in the Division of Allergy, Pulmonary and Critical Care have ...

 


Idiopathic Pulmonary Fibrosis Market Overview, Development, Innovation Directors, Symptoms, Trends and Forecast - The Financial



Idiopathic Pulmonary Fibrosis Market Overview, Development, Innovation Directors, Symptoms, Trends and Forecast 
The Financial
Idiopathic Pulmonary Fibrosis Market Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 ? marketed, Phase III products, Drugs Profiles and route of synthesis. The Idiopathic Pulmonary Fibrosis Market report is an in-depth market ...

and more » 


Researchers develop gene therapy for idiopathic pulmonary fibrosis - News-Medical.net



News-Medical.net
 
Researchers develop gene therapy for idiopathic pulmonary fibrosis 
News-Medical.net
In pulmonary fibrosis, there is extensive formation of scars over the lung tissues. This progressively causes loss of respiratory functions. There are multiple causes for fibrosis to develop including environmental toxins. However, researchers agree ...

 


Kadmon Announces Positive Topline Results from Phase 2 Study of KD025 in Idiopathic Pulmonary Fibrosis - Business Wire (press release)



Business Wire (press release)
 
Kadmon Announces Positive Topline Results from Phase 2 Study of KD025 in Idiopathic Pulmonary Fibrosis 
Business Wire (press release)
NEW YORK--(BUSINESS WIRE)--Kadmon Holdings, Inc. (NYSE:KDMN) today announced topline results from an ongoing Phase 2 clinical trial evaluating KD025, its Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, in patients with idiopathic pulmonary ...
Kadmon ROCKs Markets Insider

all 2 news articles » 


The Gift of Quiet Weekends - Pulmonary Fibrosis News



Pulmonary Fibrosis News
 
The Gift of Quiet Weekends 
Pulmonary Fibrosis News
If you have read my previous columns, you are likely aware that my life before being diagnosed with idiopathic pulmonary fibrosis (IPF) was very different than it is now. This is something I often write about because I can't believe the dramatic ...

 


Prometic's PBI-4050 Plays Dual Role in Targeting New Antifibrotic Pathway, Study Says - Pulmonary Fibrosis News



Pulmonary Fibrosis News
 
Prometic's PBI-4050 Plays Dual Role in Targeting New Antifibrotic Pathway, Study Says 
Pulmonary Fibrosis News
Therefore, by targeting this novel antifibrotic pathway, PBI-4050 and its analogues have the potential to delay or even reverse the progression of fibrotic diseases,? Gagnon said. The benefits of PBI-4050 seen in animal models also were demonstrated in ...

 


Idiopathic Pulmonary Fibrosis Drug Market Development, Market Trends, Key Driven Factors, Segmentation And ... - Facts of Week



The Honest Newspaper
 
Idiopathic Pulmonary Fibrosis Drug Market Development, Market Trends, Key Driven Factors, Segmentation And ... 
Facts of Week
The Idiopathic Pulmonary Fibrosis Drug Market report is source of key information about the Market, including invaluable facts and figures, expert opinions, and the latest developments across the globe. The Idiopathic Pulmonary Fibrosis Drug Market ...
Idiopathic Pulmonary Fibrosis Market Epidemiology, Disease, Symptoms, Risk Factors, Diagnosis and Forecast 2027 The Columnist

all 10 news articles » 


CAROLYN M. MCGIVERN - Youngstown Vindicator



Youngstown Vindicator
 
CAROLYN M. MCGIVERN 
Youngstown Vindicator
BOARDMAN - Carolyn M. McGivern, 80 years young, wife of Robert E. McGivern, passed away peacefully at home on Feb. 15, 2018, after a five-year battle with Idiopathic Pulmonary Fibrosis (IPF). Born on May 25, 1937, in North Braddock, Pa., to William and ...

 


Prometic's PBI-4050 Regulates 2 Receptors Key to Fibrosis Development, Study Shows - Lung Disease News



Lung Disease News
 
Prometic's PBI-4050 Regulates 2 Receptors Key to Fibrosis Development, Study Shows 
Lung Disease News
Prometic Life Sciences is launching a Phase 3 clinical trial to test PBI-4050's effectiveness as a therapy for idiopathic pulmonary fibrosis. Enrollment is expected to begin by mid-2018. The therapy has been tested in animal models and also showed ...